NasdaqGS:NBIXBiotechs
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)?
In February 2026, Neurocrine Biosciences reported that fourth-quarter 2025 revenue rose to US$805.5 million and net income to US$153.7 million, with full-year revenue reaching US$2.86 billion and net income US$478.6 million, alongside higher basic and diluted earnings per share from continuing operations versus 2024.
The company also issued 2026 guidance calling for INGREZZA net product sales of US$2.70 billion to US$2.80 billion, underscoring the central role of this flagship therapy in...